Pelcitoclax
- Generic Name
- Pelcitoclax
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C57H66ClF4N6O11PS4
- CAS Number
- 1619923-36-2
- Unique Ingredient Identifier
- 317UBD60ML
- Background
Pelcitoclax is under investigation in clinical trial NCT04210037 (Study of Combination APG-1252 Plus Paclitaxel in Patients With Relapsed/refractory Small Cell Lung Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
- Conditions
- Advanced Endometrial CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaMetastatic Endometrial CarcinomaMetastatic Platinum-Resistant Ovarian CarcinomaRecurrent Endometrial CarcinomaStage IV Uterine Corpus Cancer AJCC v8Metastatic Fallopian Tube CarcinomaMetastatic Primary Peritoneal CarcinomaRecurrent Fallopian Tube Carcinoma
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT05691504
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04893759
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.